🚀 VC round data is live in beta, check it out!
Liaoning Chengda Biotech Valuation Multiples
Discover revenue and EBITDA valuation multiples for Liaoning Chengda Biotech and similar public comparables like Jiangxi Fushine Pharma, Immatics, Ab&B Bio-Tech, Lepu Biopharma and more.
Liaoning Chengda Biotech Overview
About Liaoning Chengda Biotech
Liaoning Chengda Biotechnology Co Ltd is engaged in the research and development, production and sales of human vaccines.
Founded
2002
HQ
Employees
N/A
Website
Sectors
Financials (FY)
EV
$747M
Liaoning Chengda Biotech Financials
Liaoning Chengda Biotech reported last fiscal year revenue of $246M and EBITDA of $85M.
In the same fiscal year, Liaoning Chengda Biotech generated $204M in gross profit, $85M in EBITDA, and $50M in net income.
Revenue (LTM)
Liaoning Chengda Biotech P&L
In the most recent fiscal year, Liaoning Chengda Biotech reported revenue of $246M and EBITDA of $85M.
Liaoning Chengda Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $246M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $204M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 83% | XXX | XXX | XXX |
| EBITDA | — | XXX | $85M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 34% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 27% | XXX | XXX | XXX |
| Net Profit | — | XXX | $50M | XXX | XXX | XXX |
| Net Margin | — | XXX | 20% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Liaoning Chengda Biotech Stock Performance
Liaoning Chengda Biotech has current market cap of $1B, and enterprise value of $747M.
Market Cap Evolution
Liaoning Chengda Biotech's stock price is $3.57.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $747M | $1B | -1.7% | XXX | XXX | XXX | $0.12 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialLiaoning Chengda Biotech Valuation Multiples
Liaoning Chengda Biotech trades at 3.0x EV/Revenue multiple, and 8.8x EV/EBITDA.
EV / Revenue (LTM)
Liaoning Chengda Biotech Financial Valuation Multiples
As of April 18, 2026, Liaoning Chengda Biotech has market cap of $1B and EV of $747M.
Equity research analysts estimate Liaoning Chengda Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Liaoning Chengda Biotech has a P/E ratio of 29.6x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $747M | XXX | $747M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 3.0x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 8.8x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 11.2x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 3.7x | XXX | XXX | XXX |
| P/E | — | XXX | 29.6x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 36.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Liaoning Chengda Biotech Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Liaoning Chengda Biotech Margins & Growth Rates
Liaoning Chengda Biotech's revenue in the last fiscal year declined by (4%).
Liaoning Chengda Biotech Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (4%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 34% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (18%) | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 23% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 13% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 17% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 56% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Liaoning Chengda Biotech Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Liaoning Chengda Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Jiangxi Fushine Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Immatics | XXX | XXX | XXX | XXX | XXX | XXX |
| Ab&B Bio-Tech | XXX | XXX | XXX | XXX | XXX | XXX |
| Lepu Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| AtaiBeckley | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Liaoning Chengda Biotech M&A Activity
Liaoning Chengda Biotech acquired XXX companies to date.
Last acquisition by Liaoning Chengda Biotech was on XXXXXXXX, XXXXX. Liaoning Chengda Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Liaoning Chengda Biotech
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialLiaoning Chengda Biotech Investment Activity
Liaoning Chengda Biotech invested in XXX companies to date.
Liaoning Chengda Biotech made its latest investment on XXXXXXXX, XXXXX. Liaoning Chengda Biotech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Liaoning Chengda Biotech
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Liaoning Chengda Biotech
| When was Liaoning Chengda Biotech founded? | Liaoning Chengda Biotech was founded in 2002. |
| Where is Liaoning Chengda Biotech headquartered? | Liaoning Chengda Biotech is headquartered in China. |
| Is Liaoning Chengda Biotech publicly listed? | Yes, Liaoning Chengda Biotech is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Liaoning Chengda Biotech? | Liaoning Chengda Biotech trades under 688739 ticker. |
| When did Liaoning Chengda Biotech go public? | Liaoning Chengda Biotech went public in 2021. |
| Who are competitors of Liaoning Chengda Biotech? | Liaoning Chengda Biotech main competitors are Jiangxi Fushine Pharma, Immatics, Ab&B Bio-Tech, Lepu Biopharma. |
| What is the current market cap of Liaoning Chengda Biotech? | Liaoning Chengda Biotech's current market cap is $1B. |
| What is the current revenue of Liaoning Chengda Biotech? | Liaoning Chengda Biotech's last fiscal year revenue is $246M. |
| What is the current EV/Revenue multiple of Liaoning Chengda Biotech? | Current revenue multiple of Liaoning Chengda Biotech is 3.0x. |
| Is Liaoning Chengda Biotech profitable? | No, Liaoning Chengda Biotech is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.